Metagenomi Therapeutics (MGX) Accounts Payables (2023 - 2026)
Metagenomi Therapeutics (MGX) posted quarterly Accounts Payables of $2.4 million for Q1 2026, down 10.19% year-over-year from $2.7 million in Q1 2025, and up 61.05% quarter-over-quarter from $1.5 million in Q4 2025.
Metagenomi Therapeutics (MGX) Accounts Payables (2023 - 2026) Analysis & Trends
Metagenomi Therapeutics (MGX) has reported Accounts Payables for 4 consecutive years, with $2.4 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Accounts Payables fell 10.19% year-over-year to $2.4 million; the TTM figure through Mar 2026 stood at $2.4 million (down 10.19% YoY), while the FY2025 annual figure was $1.5 million, up 179.36% from the prior year.
- Accounts Payables improved to $2.4 million in Q1 2026 per MGX's latest filing, from $1.5 million in the prior quarter.
- Across five years, Accounts Payables topped out at $6.8 million in Q1 2024 and bottomed at $533000.0 in Q4 2024.
- Historically, Accounts Payables has averaged $2.6 million across 4 years, with a median of $2.5 million in 2025.
- Annual changes were most pronounced in 2024 — Accounts Payables plunged 70.24% — and 2025, when it jumped 179.36%.
- Metagenomi Therapeutics' Accounts Payables stood at $1.8 million in 2023, then slumped by 70.24% to $533000.0 in 2024, then surged by 179.36% to $1.5 million in 2025, then surged by 61.05% to $2.4 million in 2026.
- Business Quant data shows MGX's Accounts Payables at $2.4 million in Q1 2026, $1.5 million in Q4 2025, and $1.2 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Accounts Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.90 Bn | 131.05 Bn | 2.84 Bn | 429.50 Mn |
| 2 | Regeneron Pharmaceuticals | 86.10 Bn | 78.11 Bn | 3.93 Bn | 1.16 Bn |
| 3 | Argenx Se | 65.56 Bn | 60.37 Bn | 1.37 Bn | 1.52 Bn |
| 4 | Moderna | 55.82 Bn | 50.68 Bn | 52.00 Mn | 167.00 Mn |
| 5 | BeOne Medicines | 42.14 Bn | 37.04 Bn | 1.53 Bn | 470.30 Mn |
| 6 | Alnylam Pharmaceuticals | 31.67 Bn | 28.36 Bn | 992.69 Mn | 108.02 Mn |
| 7 | BioNTech SE | 27.74 Bn | 9.35 Bn | 668.28 Mn | 622.65 Mn |
| 8 | Insmed | 27.53 Bn | 26.37 Bn | 358.27 Mn | 428.93 Mn |
| 9 | Royalty Pharma | 27.38 Bn | 26.54 Bn | - | 35.57 Mn |
| 10 | Metagenomi Therapeutics | 46.51 Mn | 46.51 Mn | - | 2.60 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 2.60 Mn |
| Mar 31, 2026 | 2.40 Mn |
| Dec 31, 2025 | 1.49 Mn |
| Sep 30, 2025 | 1.22 Mn |
| Jun 30, 2025 | 2.89 Mn |
| Mar 31, 2025 | 2.67 Mn |
| Dec 31, 2024 | 533,000.00 |
| Sep 30, 2024 | 3.10 Mn |
| Jun 30, 2024 | 3.45 Mn |
| Mar 31, 2024 | 6.84 Mn |
| Dec 31, 2023 | 1.79 Mn |